Bristol Myers Squibb (BMS) has signed an agreement for an exclusive worldwide licence to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy programme.
Merck (MSD) has partnered with Dragonfly Therapeutics for the discovery, development and commercialisation of drug candidates across oncology, infectious disease and immune disorder indications.
Dragonfly Therapeutics, Inc today announced that it has entered into an agreement with Celgene Corporation and its subsidiaries ("Celgene") to research...